Transplant International (Dec 2023)
Primary Graft Function and 5 Year Insulin Independence After Pancreas and Islet Transplantation for Type 1 Diabetes: A Retrospective Parallel Cohort Study
- Mikael Chetboun,
- Mikael Chetboun,
- Mikael Chetboun,
- Mikael Chetboun,
- Christophe Masset,
- Christophe Masset,
- Mehdi Maanaoui,
- Mehdi Maanaoui,
- Mehdi Maanaoui,
- Mehdi Maanaoui,
- Frédérique Defrance,
- Valéry Gmyr,
- Valéry Gmyr,
- Valéry Gmyr,
- Violeta Raverdy,
- Violeta Raverdy,
- Violeta Raverdy,
- Violeta Raverdy,
- Thomas Hubert,
- Thomas Hubert,
- Thomas Hubert,
- Caroline Bonner,
- Caroline Bonner,
- Caroline Bonner,
- Lisa Supiot,
- Clarisse Kerleau,
- Gilles Blancho,
- Gilles Blancho,
- Julien Branchereau,
- Julien Branchereau,
- Georges Karam,
- Georges Karam,
- Ismaël Chelghaf,
- Aurélie Houzet,
- Magali Giral,
- Magali Giral,
- Claire Garandeau,
- Jacques Dantal,
- Jacques Dantal,
- Kristell Le Mapihan,
- Arnaud Jannin,
- Marc Hazzan,
- Robert Caiazzo,
- Robert Caiazzo,
- Robert Caiazzo,
- Robert Caiazzo,
- Julie Kerr-Conte,
- Julie Kerr-Conte,
- Julie Kerr-Conte,
- Marie-Christine Vantyghem,
- Marie-Christine Vantyghem,
- Marie-Christine Vantyghem,
- Marie-Christine Vantyghem,
- Diego Cantarovich,
- François Pattou,
- François Pattou,
- François Pattou,
- François Pattou
Affiliations
- Mikael Chetboun
- Univ Lille, U1190 - EGID, Lille, France
- Mikael Chetboun
- Inserm, U1190, Lille, France
- Mikael Chetboun
- Institut Pasteur de Lille, Lille, France
- Mikael Chetboun
- CHU Lille, Department of General, Endocrine and Metabolic Surgery, Lille, France
- Christophe Masset
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- Christophe Masset
- Nantes Université, Inserm, UMR 1064, Center for Research in Transplantation and Translational Immunology, Nantes, France
- Mehdi Maanaoui
- Univ Lille, U1190 - EGID, Lille, France
- Mehdi Maanaoui
- Inserm, U1190, Lille, France
- Mehdi Maanaoui
- Institut Pasteur de Lille, Lille, France
- Mehdi Maanaoui
- CHU Lille, Department of Nephrology, Lille, France
- Frédérique Defrance
- CHU Lille, Department of Endocrinology, Diabetology and Metabolism, Lille, France
- Valéry Gmyr
- Univ Lille, U1190 - EGID, Lille, France
- Valéry Gmyr
- Inserm, U1190, Lille, France
- Valéry Gmyr
- Institut Pasteur de Lille, Lille, France
- Violeta Raverdy
- Univ Lille, U1190 - EGID, Lille, France
- Violeta Raverdy
- Inserm, U1190, Lille, France
- Violeta Raverdy
- Institut Pasteur de Lille, Lille, France
- Violeta Raverdy
- CHU Lille, Department of General, Endocrine and Metabolic Surgery, Lille, France
- Thomas Hubert
- Univ Lille, U1190 - EGID, Lille, France
- Thomas Hubert
- Inserm, U1190, Lille, France
- Thomas Hubert
- Institut Pasteur de Lille, Lille, France
- Caroline Bonner
- Univ Lille, U1190 - EGID, Lille, France
- Caroline Bonner
- Inserm, U1190, Lille, France
- Caroline Bonner
- Institut Pasteur de Lille, Lille, France
- Lisa Supiot
- Nantes Université, Inserm, UMR 1064, Center for Research in Transplantation and Translational Immunology, Nantes, France
- Clarisse Kerleau
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- Gilles Blancho
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- Gilles Blancho
- Nantes Université, Inserm, UMR 1064, Center for Research in Transplantation and Translational Immunology, Nantes, France
- Julien Branchereau
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- Julien Branchereau
- Nantes Université, Inserm, UMR 1064, Center for Research in Transplantation and Translational Immunology, Nantes, France
- Georges Karam
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- Georges Karam
- Nantes Université, Inserm, UMR 1064, Center for Research in Transplantation and Translational Immunology, Nantes, France
- Ismaël Chelghaf
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- Aurélie Houzet
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- Magali Giral
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- Magali Giral
- Nantes Université, Inserm, UMR 1064, Center for Research in Transplantation and Translational Immunology, Nantes, France
- Claire Garandeau
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- Jacques Dantal
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- Jacques Dantal
- Nantes Université, Inserm, UMR 1064, Center for Research in Transplantation and Translational Immunology, Nantes, France
- Kristell Le Mapihan
- CHU Lille, Department of Endocrinology, Diabetology and Metabolism, Lille, France
- Arnaud Jannin
- CHU Lille, Department of Endocrinology, Diabetology and Metabolism, Lille, France
- Marc Hazzan
- CHU Lille, Department of Nephrology, Lille, France
- Robert Caiazzo
- Univ Lille, U1190 - EGID, Lille, France
- Robert Caiazzo
- Inserm, U1190, Lille, France
- Robert Caiazzo
- Institut Pasteur de Lille, Lille, France
- Robert Caiazzo
- CHU Lille, Department of General, Endocrine and Metabolic Surgery, Lille, France
- Julie Kerr-Conte
- Univ Lille, U1190 - EGID, Lille, France
- Julie Kerr-Conte
- Inserm, U1190, Lille, France
- Julie Kerr-Conte
- Institut Pasteur de Lille, Lille, France
- Marie-Christine Vantyghem
- Univ Lille, U1190 - EGID, Lille, France
- Marie-Christine Vantyghem
- Inserm, U1190, Lille, France
- Marie-Christine Vantyghem
- Institut Pasteur de Lille, Lille, France
- Marie-Christine Vantyghem
- CHU Lille, Department of Endocrinology, Diabetology and Metabolism, Lille, France
- Diego Cantarovich
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France
- François Pattou
- Univ Lille, U1190 - EGID, Lille, France
- François Pattou
- Inserm, U1190, Lille, France
- François Pattou
- Institut Pasteur de Lille, Lille, France
- François Pattou
- CHU Lille, Department of General, Endocrine and Metabolic Surgery, Lille, France
- DOI
- https://doi.org/10.3389/ti.2023.11950
- Journal volume & issue
-
Vol. 36
Abstract
In islet transplantation (ITx), primary graft function (PGF) or beta cell function measured early after last infusion is closely associated with long term clinical outcomes. We investigated the association between PGF and 5 year insulin independence rate in ITx and pancreas transplantation (PTx) recipients. This retrospective multicenter study included type 1 diabetes patients who underwent ITx in Lille and PTx in Nantes from 2000 to 2022. PGF was assessed using the validated Beta2-score and compared to normoglycemic control subjects. Subsequently, the 5 year insulin independence rates, as predicted by a validated PGF-based model, were compared to the actual rates observed in ITx and PTx patients. The study enrolled 39 ITx (23 ITA, 16 IAK), 209 PTx recipients (23 PTA, 14 PAK, 172 SPK), and 56 normoglycemic controls. Mean[SD] PGF was lower after ITx (ITA 22.3[5.2], IAK 24.8[6.4], than after PTx (PTA 38.9[15.3], PAK 36.8[9.0], SPK 38.7[10.5]), and lower than mean beta-cell function measured in normoglycemic control: 36.6[4.3]. The insulin independence rates observed at 5 years after PTA and PAK aligned with PGF predictions, and was higher after SPK. Our results indicate a similar relation between PGF and 5 year insulin independence in ITx and solitary PTx, shedding new light on long-term transplantation outcomes.
Keywords